Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG. La Monica S, et al. Among authors: capelletti m. Biochem Pharmacol. 2009 Sep 1;78(5):460-8. doi: 10.1016/j.bcp.2009.04.033. Epub 2009 May 7. Biochem Pharmacol. 2009. PMID: 19427302
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A. Tiseo M, et al. Among authors: capelletti m. J Thorac Oncol. 2008 Oct;3(10):1104-11. doi: 10.1097/JTO.0b013e3181861d67. J Thorac Oncol. 2008. PMID: 18827605 Free article.
MET and ALK as targets for the treatment of NSCLC.
Capelletti M, Gelsomino F, Tiseo M. Capelletti M, et al. Curr Pharm Des. 2014;20(24):3914-32. doi: 10.2174/13816128113196660760. Curr Pharm Des. 2014. PMID: 24138716 Review.
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A. Tiseo M, et al. Among authors: capelletti m. Lung Cancer. 2010 Mar;67(3):355-60. doi: 10.1016/j.lungcan.2009.04.021. Epub 2009 May 26. Lung Cancer. 2010. PMID: 19473722
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A. Loprevite M, et al. Among authors: capelletti m. Clin Cancer Res. 2007 Nov 1;13(21):6518-26. doi: 10.1158/1078-0432.CCR-07-0805. Clin Cancer Res. 2007. PMID: 17975165
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Musolino A, et al. Among authors: capelletti m. J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
68 results